---
schema_version: "secwatch.filing_event.v1"
accession: "0000944809-22-000029"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T17:28:38.280274+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO Health acquires ModeX Therapeutics for $300M in stock; appoints Dr. Zerhouni as President

## Summary
- Merger consideration of $300M paid via 89,907,310 shares of OPKO common stock.
- Dr. Elias Zerhouni appointed President and Vice Chairman; Dr. Gary Nabel named Chief Innovation Officer and director.
- Alexis Borisy appointed to board; receives 312,612 restricted shares and options.
- Frost Gamma Investments Trust and holders of ~88% of consideration shares subject to 4-year lockup.
- Zerhouni employment: $900K base, target bonus ≥50%; Nabel: $750K base, target bonus ≥50%.

## SEC filing metadata
- accession: 0000944809-22-000029
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/0000944809-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/opk-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000944809-22-000029
- JSON: https://secwatch.observer/filing/0000944809-22-000029.json
- Plain text: https://secwatch.observer/filing/0000944809-22-000029.txt

## Key facts
- Executive change
  Alexis Borisy was appointed as director at OPKO HEALTH, INC..
  - Action: appointed
  - Role: director
  source text: On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/0000944809-22-000029-index.htm
- Executive change
  Gary Nabel was appointed as Chief Innovation Officer and a director at OPKO HEALTH, INC..
  - Action: appointed
  - Role: Chief Innovation Officer and a director
  source text: On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/0000944809-22-000029-index.htm
- Executive change
  Elias Zerhouni was appointed as President and Vice Chairman of the Board at OPKO HEALTH, INC..
  - Action: appointed
  - Role: President and Vice Chairman of the Board
  source text: On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000094480922000029/0000944809-22-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.